Home > Products > Featured products

Vafidemstat (ORY-2001)

  Cat. No.:  DC11106   Featured
Chemical Structure
1357362-02-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Vafidemstat (ORY-2001) is an oral, brain penetrant drug that inhibits LSD1 and MAOB by reducing cognitive impairment, including memory loss and neuroinflammation. It also has neuroprotective effects.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 1357362-02-7
Chemical Name: 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-[(1R,2S)-2-[4-(phenylmethoxy)phenyl]cyclopropyl]-
Synonyms: ORY2001,ORY 2001,ORY-2001
SMILES: O1C(N)=NN=C1CN[C@H]1C[C@@H]1C1=CC=C(OCC2=CC=CC=C2)C=C1
Formula: C19H20N4O2
M.Wt: 336.395
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Vafidemstat is a dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor.
Target: LSD1/MAO-B[1]
In Vitro: Vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor, is a novel epigenetic agent for the treatment of neurodegenerative diseases. LSD1 is a protein that participates in transcription regulation complexes; its modulation can be used to tweak transcriptional imbalances in neurodegenerative disease and redress neuroinflammation and cognitive deficit[1]. Vafidemstat (ORY-2001) can be used in the treatment of Alzheimer's disease[2].
References: [1]. ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer’s and Parkinson’s diseases [2]. ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2018.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC11703 T-3775440 hydrochloride T-3775440 hydrochloride is a novel potent, selecitve, irreversible LSD1 inhibitor with IC50 of 2.1 nM.
DC11400 Seclidemstat（SP-2577） Seclidemstat(SP-2577) is a potent LSD1 inhibitor, with a mean IC50 of 127 nM.
DC7636 RN-1 Hydrochloride RN-1 is an inhibitor of lysine specific demethylase 1 (LSD1); exhibits selectivity for LSD1 over monoamine oxidase (MAO)-A and MAO-B (IC50 values are 70 nM, 0.51 and 2.79 μM respectively.
DC5204 OG-L002 OG-L002 is a potent and specific LSD1 inhibitor with IC50 of 20 nM, exhibiting 36- and 69-fold selectivity over MAO-B and MAO-A, respectively.
DC7740 ML-324 ML-324 is a JMJD2 histone demethylase inhibitor (JMJD2 IC50 = 920 nM)
DC11106 Vafidemstat (ORY-2001) Vafidemstat (ORY-2001) is an oral, brain penetrant drug that inhibits LSD1 and MAOB by reducing cognitive impairment, including memory loss and neuroinflammation. It also has neuroprotective effects.
DC10586 KDM4D-IN-1 KDM4D-IN-1 is a new histone lysine demethylase 4D (KDM4D) inhibitor with an IC50 value of 0.41±0.03 μM.
DC7614 IOX1 IOX1 is a potent and broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases.
DC8491 GSK2879552 GSK2879552 is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.
DC8385 Disodium (R)-2-Hydroxyglutarate Disodium (R)-2-Hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases with Ki of 0.628 mM.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia